Gertrude Nakigozi1, Fredrick E Makumbi, John B Bwanika, Lynn Atuyambe, Steven J Reynolds, Godfrey Kigozi, Fred Nalugoda, Larry W Chang, Valerian Kiggundu, David Serwadda, Maria J Wawer, Ronald H Gray, Moses R Kamya. 1. *Rakai Health Sciences Program, Kalisizo, Uganda; †School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda; ‡Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; §Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD; ‖Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD; ¶Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; #Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Abstract
BACKGROUND: Data are limited on effects of household or community support persons ("care buddies") on enrollment into and adherence to pre-antiretroviral HIV care. We assessed the impact of care buddies on adherence to HIV clinic appointments, HIV progression, and conduct of daily life among pre-antiretroviral therapy (pre-ART) HIV-infected individuals in Rakai, Uganda. METHODS: A total of 1209 HIV-infected pre-ART patients aged ≥15 years were randomized to standard of care (SOC) (n = 604) or patient-selected care buddy (PSCB) (n = 605) and followed at 6 and 12 months. Outcomes were adherence to clinic visits, HIV disease progression, and self-reported conduct of daily life. Incidence and prevalence rate ratios and 95% confidence intervals (CIs) were used to assess outcomes in the intent-to-treat and as-treated analyses. RESULTS: Baseline characteristics were comparable. In the intent to treat analysis, both arms were comparable with respect to adherence to CD4 monitoring visits [adjusted prevalence risk ratio (adjPRR), 0.98; 95% CI: 0.93 to 1.04; P = 0.529], and ART eligibility (adjPRR, 1.00; 95% CI: 0.77 to 1.31; P = 0.946). Good conduct of daily life was significantly higher in the PSCB than the SOC arm (adjPRR, 1.08; 95% CI: 1.03 to 1.13; P = 0.001). More men (61%) compared with women (30%) selected spouses/partners as buddies (P < 0.0001). Twenty-two percent of PSCB arm participants discontinued use of buddies. CONCLUSIONS: In pre-ART persons, having care buddies improved the conduct of daily life of the HIV-infected patients but had no effect on HIV disease progression and only limited effect on clinic appointment adherence.
RCT Entities:
BACKGROUND: Data are limited on effects of household or community support persons ("care buddies") on enrollment into and adherence to pre-antiretroviral HIV care. We assessed the impact of care buddies on adherence to HIV clinic appointments, HIV progression, and conduct of daily life among pre-antiretroviral therapy (pre-ART) HIV-infected individuals in Rakai, Uganda. METHODS: A total of 1209 HIV-infected pre-ART patients aged ≥15 years were randomized to standard of care (SOC) (n = 604) or patient-selected care buddy (PSCB) (n = 605) and followed at 6 and 12 months. Outcomes were adherence to clinic visits, HIV disease progression, and self-reported conduct of daily life. Incidence and prevalence rate ratios and 95% confidence intervals (CIs) were used to assess outcomes in the intent-to-treat and as-treated analyses. RESULTS: Baseline characteristics were comparable. In the intent to treat analysis, both arms were comparable with respect to adherence to CD4 monitoring visits [adjusted prevalence risk ratio (adjPRR), 0.98; 95% CI: 0.93 to 1.04; P = 0.529], and ART eligibility (adjPRR, 1.00; 95% CI: 0.77 to 1.31; P = 0.946). Good conduct of daily life was significantly higher in the PSCB than the SOC arm (adjPRR, 1.08; 95% CI: 1.03 to 1.13; P = 0.001). More men (61%) compared with women (30%) selected spouses/partners as buddies (P < 0.0001). Twenty-two percent of PSCB arm participants discontinued use of buddies. CONCLUSIONS: In pre-ART persons, having care buddies improved the conduct of daily life of the HIV-infectedpatients but had no effect on HIV disease progression and only limited effect on clinic appointment adherence.
Authors: Michael A Koenig; Tom Lutalo; Feng Zhao; Fred Nalugoda; Fred Wabwire-Mangen; Noah Kiwanuka; Jennifer Wagman; David Serwadda; Maria Wawer; Ron Gray Journal: Bull World Health Organ Date: 2003-03-11 Impact factor: 9.408
Authors: Elena Losina; Ingrid V Bassett; Janet Giddy; Senica Chetty; Susan Regan; Rochelle P Walensky; Douglas Ross; Callie A Scott; Lauren M Uhler; Jeffrey N Katz; Helga Holst; Kenneth A Freedberg Journal: PLoS One Date: 2010-03-04 Impact factor: 3.240
Authors: Lieve Van der Paal; Leigh Anne Shafer; Jim Todd; Billy N Mayanja; Jimmy A G Whitworth; Heiner Grosskurth Journal: AIDS Date: 2007-11 Impact factor: 4.177
Authors: Vu Van Tam; Mattias Larsson; Anastasia Pharris; Björn Diedrichs; Hoa Phuong Nguyen; Chuc Thi Kim Nguyen; Phuc Dang Ho; Gaetano Marrone; Anna Thorson Journal: Health Qual Life Outcomes Date: 2012-05-18 Impact factor: 3.186
Authors: Charles A S Karamagi; James K Tumwine; Thorkild Tylleskar; Kristian Heggenhougen Journal: BMC Public Health Date: 2006-11-20 Impact factor: 3.295
Authors: Katharina Kranzer; Darshini Govindasamy; Nathan Ford; Victoria Johnston; Stephen D Lawn Journal: J Int AIDS Soc Date: 2012-11-19 Impact factor: 5.396
Authors: Laura M Bogart; Mosepele Mosepele; Nthabiseng Phaladze; Bright Lekoko; David J Klein; Sarah MacCarthy; Harold D Green Journal: J Acquir Immune Defic Syndr Date: 2018-06-01 Impact factor: 3.731
Authors: Jean B Nachega; Olatunji Adetokunboh; Olalekan A Uthman; Amy W Knowlton; Frederick L Altice; Mauro Schechter; Omar Galárraga; Elvin Geng; Karl Peltzer; Larry W Chang; Gilles Van Cutsem; Shabbar S Jaffar; Nathan Ford; Claude A Mellins; Robert H Remien; Edward J Mills Journal: Curr HIV/AIDS Rep Date: 2016-10 Impact factor: 5.071
Authors: Joia S Mukherjee; Danika Barry; Robert D Weatherford; Ishaan K Desai; Paul E Farmer Journal: Curr HIV/AIDS Rep Date: 2016-12 Impact factor: 5.071
Authors: M Kate Grabowski; David M Serwadda; Ronald H Gray; Gertrude Nakigozi; Godfrey Kigozi; Joseph Kagaayi; Robert Ssekubugu; Fred Nalugoda; Justin Lessler; Thomas Lutalo; Ronald M Galiwango; Fred Makumbi; Xiangrong Kong; Donna Kabatesi; Stella T Alamo; Steven Wiersma; Nelson K Sewankambo; Aaron A R Tobian; Oliver Laeyendecker; Thomas C Quinn; Steven J Reynolds; Maria J Wawer; Larry W Chang Journal: N Engl J Med Date: 2017-11-30 Impact factor: 91.245